QualityStocks would like to highlight Pluristem Therapeutics, Inc. (NASDAQ: PSTI). The company is dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. Pluristem is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source.
In the company’s news yesterday,
Pluristem Therapeutics Inc. announced that its Senior Scientist, Racheli Ofir, Ph.D., has been invited by the Centro di Ricerca E. Menni (CREM), Fondazione Poliambulanza, Brescia, Italy, to present at a workshop titled “Placenta-Derived Cells for Treatment of Inflammatory Diseases: Moving Toward Clinical Applications” on March 13, 2009.
Zami Aberman, Chairman, President and CEO of Pluristem, commented, “The research and medical communities are very interested in the placenta as a superior source for cell therapy. This entire workshop is devoted to studies performed on placental cells and their potential for becoming therapeutic products. At Pluristem, we believe the placenta will play a major role in the developing cell therapy market. Based on substantial pre-clinical data, we have developed a pipeline of placental-derived mesenchymal-like stromal cell products, the first one being PLX-PAD for the treatment of critical limb ischemia.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
